Clinical study of high-risk HPV genotyping in risk stratification and management of cervical cancer screening

Abstract

Listen

Translate article

Objective To evaluate the clinical value of high-risk HPV(HR-HPV)genotyping in risk stratification and management of cervical cancer screening. Methods Totally 9 331 women underwent routine cervical cancer screening at the first time of medical visit in gynecological clinic at Taizhou Hospital of Zhejiang Province. Cervical samples were collected by liquid-based method and analyzed for cytology and HPV genotyping (Co-testing). The clinical value of HPV 16 and 18 genotyping in risk stratification and management of cervical cancer screening was evaluated. Results Patients were comprised of women aged 30 to 65 years with HPV-positive 21.6% (HR-HPV infection accounting for 79.0%), with abnormal cytology 5.0% (HR-HPV infection accounting for 56.2%). The sensitivity of HR-HPV genotyping for CIN2+ was significantly higher than that of cytology using a positive cut point of ASCUS(χ2=42.36, P<0.05). Histopathological diagnosis of CIN2+ which in 80 cases (13.5%), including HR-HPV types were 74 cases (92.5%) and abnormal cervical cytology were 59 cases (73.8%). The positive of HR-HPV infection was a significant factor associated with the development of CIN (χ2=10.00, P<0.05). Conclusions The sensitivity of HR-HPV genotyping in cervical cancer screening was significantly higher than cytology as suspicious or mildly abnormal cytology results who were followed up diversion can be found cytology missed cervical tissue lesions, thereby reducing cancer precancerous lesions and cervical cancer incidence and mortality. Key words: Papillomavirus human; Genotype; Cervix neoplasms; Cervical intraepithelial neoplasia